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Chemokines and their receptors play an important role in the
development of allograft rejection through directing
mononuclear cell invasion of the graft. To study whether
chemokine assays in the urine could prove to be predictive of
acute rejection we measured the urinary excretion of several
chemokines including fractalkine, chemokine monokine
induced by interferon-c, interferon-c-inducible protein 10,
macrophage inflammatory protein-3a, granzyme B and
perforin in 215 allograft recipients and in 80 healthy control
subjects. The 67 patients with acute rejection had
significantly higher levels of all urinary chemokines
compared to the healthy controls or patients having chronic
allograft nephropathy but with stable renal function. Only
changes in urinary fractalkine differentiated patients with
acute rejection from those with acute tubular necrosis. The
7 patients who lost their graft had greater urinary fractalkine,
interferon-c and macrophage inflammatory protein-3a
concentrations than those patients with reversible acute
rejection. The area under the receiver operating characteristic
curve for fractalkine was the best indicator among all of the
markers differentiating 39 patients diagnosed with steroid-
resistant from the 28 patients with steroid-sensitive acute
rejection and in predicting graft loss. Our study shows that
measuring urinary fractalkine levels is a noninvasive
approach for detecting acute rejection where high levels
were associated with steroid-resistance and poor outcome.
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Acute renal allograft rejection is characterized by the
infiltration of activated mononuclear cells in graft tissues. It
is well known that chemokine and its receptor are important
in the development of allograft rejection by directing
mononuclear cells trafficking in the graft tissues.1 Fractalkine,
which was originally detected in umbilical vein endothelial
cells,2 is an unusual member of the chemokine family. It is
the only chemokine with three intervening amino acids
between the first two cysteine residues. Fractalkine exists on
the surface of cells where it can effectively interact with
leukocytes and capture cells through a direct interaction with
its unique receptor: CX3CR1.3 Expression of CX3CR1 has
been demonstrated for a wide variety of cells including T
cells, monocyte/macrophages, natural killer (NK) cells, and
neutrophils.4 Fractalkine triggers the adhesion of cells
expressing CX3CR1 to endothelial cells under flow condi-
tion.5 Fractalkine may be cleaved to produce a soluble form.
It can function as a potent chemoattractant molecule.3
Therefore, fractalkine is not only an adhesion molecule to
mediate, capture, and firm adhesion of circulating T cells,
monocyte, and NK cells, but it also promotes chemotaxis of
these cells.6 Thus, the fractalkine–CX3CR1 pathway for
leukocyte trafficking and activation may be important in
the pathogenesis of acute rejection.
Histological examination of renal allograft tissue is a
golden standard for diagnosing acute rejection. However,
because of the inadequate sample size and sampling error,
there have been conflicting results of the histological
findings.7 Moreover, biopsy is limited by the invasive nature
of the procedure and cost. Noninvasive tests that could be
used for monitoring acute rejection would be of considerable
value in supplementing biopsy. Some studies revealed that
the measurement of immunological activity in serum did not
reflect the transplant status.8,9 However, urinary measure-
ment may provide a simpler tool for the diagnosis of acute
rejection.10 Approximately 30% of urinary proteins are
plasma proteins, whereas the other 70% are produced in
the kidney.11,12 Therefore, information of changes in urinary
protein excretion may reflect the state of the kidney. Urine
proteome in the transplant recipient with acute rejection was
significantly different from that in the recipient with stable
graft function.13,14
As the number of CX3CR1-expressing cells was higher in
the transplants with acute rejection when compared to
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biopsies without signs of rejection,15 we tested the hypothesis
that fractalkine would be present at high levels in urine
during acute rejection. Furthermore, comparison with a
number of variables had been proposed as possible markers
of acute rejection, including chemokine monokine induced
by interferon-g (Mig/CXCL9),16 interferon-g-inducible pro-
tein 10 (IP-10/CXCL10),17 and macrophage inflammatory
protein-3a (MIP-3a/CCL20),18 as well as cytotoxic effector
molecules (granzyme B and perforin).19 Which was a better
marker for monitoring renal transplant recipients?
RESULTS
Levels of urinary chemokines in 119 patients with No-AR
during 8 weeks after transplant
Levels of urinary fractalkine, Mig, and IP-10 were the stable
expression at different times during the first 8 weeks after
transplant, but the levels of urinary MIP-3a at 2 weeks were
higher than those at 4, 6, and 8 weeks, as shown in Table 1.
Urinary chemokines and cytotoxic effector molecules
were markers of acute renal allograft rejection
Patients with acute rejection excreted urinary fractalkine at a
significantly higher level (407.52±57.02, 95% CI:
293.68–521.35 ng/mmol creatinine) than did patients with
no abnormal histological findings (No-AR) and healthy
controls (Po0.001). Patients with acute tubular necrosis
(ATN) and chronic allograft nephropathy (CAN) excreted
urinary fractalkine at a significantly lower level
(133.76±39.71, 95% CI: 48.60–218.92 ng/mmol creatinine
(P¼ 0.002) and 96.02±32.91, 95%CI: 24.92–167.12 ng/mmol
creatinine (P¼ 0.001), respectively) than patients with acute
rejection. No-AR patients excreted urinary fractalkine at
higher levels (64.83±9.40, 95% CI: 46.22–83.44 ng/mmol
creatinine) than those of healthy controls (P¼ 0.014).
Patients with acute rejection also excreted urinary Mig, IP-
10, MIP-3a, granzyme B, and perforin at significantly higher
levels than did patients with No-AR, CAN, and healthy
controls. However, these levels in urine did not discriminate
acute rejection from ATN, as shown in Table 2.
A conventional receiver operating characteristic (ROC)
curve was constructed to determine the discriminatory power
of chemokines and cytotoxic effector molecule levels for
diagnosis of acute rejection. For differentiating acute
rejection from No-AR, the areas under the ROC curve of
fractalkine, Mig, IP-10, MIP-3a, granzyme B, and perforin
were 0.834, 0.901, 0.810, 0.734, 0.765, and 0.779, respectively,
as shown in Table 3 and Figure 1a. The cut point that
maximized the combined sensitivity and specificity for
fractalkine was 102.88 ng/mmol creatinine. At this threshold,
the sensitivity was 82.1% and the specificity was 76.5%
(Po0.001). Forward stepwise logistic regression analysis with
likelihood ratio statistic was performed between acute
rejection and No-AR patients to predict the best subset of
markers for diagnosing acute rejection. The best model where
all the markers were individually statistical was the
combination of fractalkine, IP-10, and granzyme B. This
model had a specificity of 95.0% and a sensitivity of 83.6%.
For differentiating acute rejection from ATN, the area under
the ROC curve of fractalkine was 0.734 (95% CI:
0.604–0.865), as shown in Figure 1b. The areas under the
ROC curve of other chemokines and cytotoxic effector
molecules for differentiating acute rejection from ATN was
observed to be of no statistical difference, as shown in
Table 3.
High levels of urinary fractalkine predicted steroid-resistant
acute rejection and graft loss at early stage after acute
rejection
Among the 67 patients with acute rejection, 28 with a
reversible creatinine rise after treatment with intravenous
methylprednisolone were classified as steroid-sensitive acute
rejection (SSAR), whereas 39 patients showing no improve-
ment on the following steroids were classified as steroid-
resistant acute rejection (SRAR). Patients with SRAR had
significantly greater urinary fractalkine concentration than
did those with SSAR (568.48±86.29, 95% CI: 393.80–743.17
vs 183.31±34.93, 95% CI: 111.63–254.99 ng/mmol creati-
nine, Po0.001). The ROC curve showed the sensitivity and
specificity of various cut points for levels of fractalkine to
determine the diagnosis of SRAR. The area under the ROC
curve was 0.771 (95% CI: 0.659–0.884). The cut point that
maximized the combined sensitivity and specificity for
fractalkine was 233.76 ng/mmol creatinine. At this threshold,
the sensitivity was 74.4% and the specificity was 75.0%
(Po0.001). Although the concentrations of other urinary
chemokines (Mig, IP-10, and MIP-3a) in patients with SRAR
were greater than those in patients with SSAR (Table 4), the
area under the ROC curve of fractalkine was the greatest
among those chemokines for differentiating SRAR from
SSAR (Table 5). Urinary cytotoxic effector molecules
(granzyme B and perforin) concentration did not discrimi-
nate SRAR from SSAR (Tables 4 and 5). Forward stepwise
logistic regression analysis with likelihood ratio statistic was
performed in patients with acute rejection for SRAR
prediction. The best model where all the markers were
individually statistical was fractalkine and IP-10. This model
had a specificity of 78.6% and a sensitivity of 79.5%.
Among 67 patients with acute rejection, elevated creati-
nine levels of 60 patients were successfully controlled, but
antirejection treatment was not effective in 7 patients lost
Table 1 | Levels of urinary chemokines (ng/mmol creatinine)
during the follow-up period of the first 2 months (2 4 6, and
8-weeks) after transplant in 119 patients with No-AR
2-week 4-week 6-week 8-week P-value#
Fractalkine 71.84±10.71 63.19±9.25 68.75±11.83 60.17±12.29 0.792
Mig 51.43±16.22 20.95±5.56 38.33±15.71 18.33±6.03 0.667
IP-10 3.58±2.23 1.47±0.72 2.63±1.71 1.09±0.49 0.355
MIP-3a 5.93±1.42* 1.24±0.39 0.52±0.24 0.97±0.30 o0.001
Mig, chemokine monokine induced by IFN-g; IP-10, IFN-g-inducible protein 10; MIP-
3a, macrophage inflammatory protein-3a.
#P-values were calculated with the use of Friedman test.
*MIP-3a, 2 week vs 4, 6, 8 weeks, Po0.001.
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graft within 3 months after acute rejection. A total of seven
patients with graft loss had significantly greater urinary
fractalkine concentration than 60 patients with reversible
acute rejection (809.34±210.52, 95% CI: 294.23–1324.45 vs
360.64±56.38, 95% CI: 247.82–473.45 ng/mmol creatinine,
P¼ 0.004). The ROC curve showed the sensitivity and
specificity for various cut points for levels of fractalkine to
predict worse outcomes after acute rejection. The area under
the ROC curve was 0.833 (95% CI: 0.721–0.945). The cut
point that maximized the combined sensitivity and specificity
for fractalkine was 308.67 ng/mmol creatinine. At this
threshold, the sensitivity was 100% and the specificity was
68.3% (P¼ 0.004). Although urinary Mig and MIP-3a
concentrations in patients with graft loss were greater than
those in patients with reversible acute rejection (Table 4), the
area under the ROC curve of fractalkine was the greatest
among them for predicting graft loss (Table 5). The
concentrations of IP-10, granzyme B, and perforin in patients
with graft loss and reversible acute rejection were similar and
did not predict graft loss (Table 6).
Levels of urinary chemokines after antirejection therapy
A total of 45 urinary samples were collected from patients
with reversible acute rejection after the end of antirejection
therapy at an average of 4 days (range: 1–15 days). All levels
of urinary biomarkers after antirejection therapy (fractalkine:
60.89±17.04, Mig: 37.63±16.37, IP-10: 7.05±2.87, MIP-3a:
0.97±0.37, granzyme B: 1.32±0.26, and perforin: 1.93±
0.54 ng/mmol creatinine, respectively) were lower than those
at the time of acute rejection (Po0.001).
DISCUSSION
It was identified for the first time that fractalkine in urine was
a marker of acute renal allograft rejection and predicted
response to antirejection therapy. Acute allograft rejection is
one of the most frequent complications in renal transplanta-
tion. The intensity of acute rejection and effect of treatment
have a direct impact on the long-term outcome of the graft.20
Histopathologic examination of renal biopsy is regarded as
the gold standard for diagnosing acute rejection. However,
biopsy may lead to potential complications and cannot be
performed repeatedly in the short term.21 Even after acute
rejection has been determined by biopsy, it is still difficult to
predict therapeutic response accurately. The early determina-
tion of SRAR would enable patients avoid to exposure to
unnecessarily high-dose steroids. To reduce further immuno-
logic injury, it is important that patients with SRAR should be
treated with OKT3 (monoclonal anti-CD3 antibodies),
plasma change, or both at an early stage. It would be desirable
to use noninvasive techniques to reduce biopsy procedure for
the diagnosis of acute rejection and to predict therapeutic
response. Some studies have associated acute rejection with
Table 2 | Comparison of urinary chemokines and cytotoxic effector molecule expression in acute rejection with those in No-AR,
ATN, CAN, and healthy controls (ng/mmol creatinine)
AR (n=67)
No-AR
(n=119) P-value ATN (n=15) P-value CAN (n=14) P-value
Healthy controls
(n=80) P-value
Fractalkine 407.52±57.02 64.83±9.40 o0.001 133.76±39.71 0.002 96.02±32.91 o0.001 30.53±4.78 o0.001
Mig 679.88±179.94 19.1±95.12 0.005 276.02±135.86 0.540 66.32±25.79 0.012 13.77±1.92 0.004
IP-10 191.17±49.99 1.26±0.62 0.003 80.93±38.85 0.579 0.90±0.90 0.003 0.44±0.18 0.003
MIP-3a 27.22±9.93 1.02±0.33 o0.001 11.73±3.75 0.165 0.82±0.47 0.022 1.29±0.38 o0.001
Granzyme B 13.87±3.17 1.14±0.44 0.002 6.99±2.20 0.548 0.35±0.20 0.001 1.06±0.43 0.002
Perforin 24.54±5.45 2.19±0.93 0.001 21.45±6.12 1.0 0.79±0.42 o0.001 2.28±0.72 0.001
AR, acute rejection; ATN, acute tubular necrosis; CAN, chronic allograft nephropathy; No-AR, stable renal function and no abnormal histological findings; Mig, chemokine
monokine induced by IFN-g; IP-10, IFN-g-inducible protein 10; MIP-3a, macrophage inflammatory protein-3a.
Post hoc test was used to compare the levels of chemokines and cytotoxic effector molecules in samples showing acute rejection with those in each of the four other groups
of samples.
Table 3 | Summary of ROC curves analysis (for differentiating acute rejection from No-AR as well as from ATN)
Group Area (95% CI) Cut pointa Sensitivity/specificity (%) P-value
Fractalkine AR vs No-AR 0.834 (0.770–0.899) 102.88 82.1/76.5 o0.001
AR vs ATN 0.734 (0.604–0.865) 99.33 82.1/66.7 0.005
Mig AR vs No-AR 0.901 (0.853–0.950) 24.04 83.6/83.2 o0.001
AR vs ATN 0.590 (0.440–0.740) 264.34 40.9/73.3 0.279
IP-10 AR vs No-AR 0.810 (0.736–0.885) 5.74 65.2/96.6 o0.001
AR vs ATN 0.579 (0.416–0.743) 11.24 63.1/60.0 0.339
MIP-3a AR vs No-AR 0.734 (0.655–0.814) 0.544 59.7/81.5 o0.001
AR vs ATN 0.441 (0.273–0.610) 52.54 10.6/100.0 0.481
Granzyme B AR vs No-AR 0.765 (0.688–0.843) 1.47 59.7/91.6 o0.001
AR vs ATN 0.539 (0.391–0.688) 13.36 28.4/93.3 0.636
Perforin AR vs No-AR 0.779 (0.702–0.855) 7.55 55.2/95.0 o0.001
AR vs ATN 0.466 (0.301–0.631) 73.89 7.5/100 0.679
AR, acute rejection; ATN, acute tubular necrosis; CAN, chronic allograft nephropathy; No-AR, stable renal function and no abnormal histological findings; Mig, chemokine
monokine induced by IFN-g; IP-10, IFN-g-inducible protein 10; MIP-3a, macrophage inflammatory protein-3a; CI, confidence interval.
ang/mmol creatinine.
1456 Kidney International (2008) 74, 1454–1460
o r i g i n a l a r t i c l e W Peng et al.: Urinary fractalkine is a marker of acute rejection
cytokines in urine such as adhesion molecules22 and
chemokines (Mig and IP-10). Mig and IP-10 in urine were
markers of acute rejection in renal transplantation.16,17
However, the ability of Mig and IP-10 to serve as biochemical
markers of rejection remained controversial. Urinary Mig and
IP-10 were not helpful in distinguishing acute rejection from
ATN.23 Our results proved that to be the case.
Patients with No-AR displayed similar fractalkine con-
centrations in urine at different time in an early stage after
transplant. But significant differences could be demonstrated
in urinary excretion of fractalkine between patients with No-
AR and those with acute rejection. Likewise, the levels of
urinary fractalkine of patients with acute tubular necrosis
and CAN were significantly lower than those of patients with
acute rejection. Fractalkine is detected in the vascular
endothelial cells, proximal tubular epithelial cells, and
mesangial cells in normal human kidney tissue.24,25 In vitro,
proinflammatory cytokines (tumor-necrosis factor-a and
interleukin-1) stimulate fractalkine expression on those
cells.25,26 During the acute rejection and inflammatory
process, expression of fractalkine mRNA and protein was
significantly upregulated in those intrinsic cells of the kidney
in vivo.24 The strong expression of fractalkine may direct
mononuclear expressing CX3CR1 to inflammatory sites,
including glomerular and tubulointerstitial sites. Vascular
endothelial and tubular epithelial cells expressed a great deal
of fractalkine, which generated a soluble form by proteolytic
cleavage from membrane and spilled into tubules during
acute rejection. Although patients with acute rejection
excreted urinary Mig, IP-10, and MIP-3a also at significantly
higher levels than those with No-AR, CAN, and healthy
controls, even the area under the ROC curve of Mig was
greater than that of fractalkine for differentiating acute
rejection from No-AR; these chemokine levels in urine did
not discriminate acute rejection from ATN. Previous
evidence showed that tubular epithelial cells were a major
source of urinary Mig, IP-10, and MIP-3a.16–18 Although
infiltrating mononuclear cells might contribute to the
elevation of these chemokines in urine, tubular injury was
responsible for elevating these chemokines. This might be the
reason why these chemokine levels in the urine did not
discriminate acute rejection from ATN. Meanwhile, expres-
sion of granzyme B and perforin in urine was upregulated
not only in acute rejection but also in ATN.27 Our results also
proved it.
The result showed that the level of urinary fractalkine
elevated in acute rejection; besides, the more serious the
a
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Figure 1 | Analysis by the ROC curve for fractalkine as a
marker for diagnosis of acute rejection. (a) For differentiating
acute rejection from No-AR, the area under the ROC curve was
0.834 (95% CI: 0.770–0.899) (Po0.001). (b) For differentiating
acute rejection from ATN, the area under the ROC curve was 0.734
(95% CI: 0.604–0.865).
Table 4 | Urinary biomarker expression in SSAR and SRAR as well as reversible acute rejection and graft loss (ng/mmol
creatinine)
SSAR (n=28) SRAR (n=39) P-value Reversible AR (n=60) Graft loss (n=7) P-value
Fractalkine 183.31±34.93 568.48±86.29 o0.001 360.64±56.38 809.34±210.52 0.004
Mig 197.06±68.50 1026.53±294.37 0.002 509.42±127.18 2141.03±1283.91 0.045
IP-10 59.33±34.98 280.93±78.06 0.003 195.23±54.73 129.08±54.54 0.502
MIP-3a 1.10±0.41 45.96±16.48 0.001 20.79±9.27 82.29±50.62 0.025
Granzyme B 8.72±1.76 17.57±5.25 0.504 11.01±2.12 38.39±23.83 0.479
Perforin 16.35±5.42 30.43±8.45 0.646 19.82±4.17 65.01±36.81 0.316
Mig, chemokine monokine induced by IFN-g; IP-10, IFN-g-inducible protein 10; MIP-3a, macrophage inflammatory protein-3a; SSAR, steroid-sensitive acute rejection; SRAR,
steroid-resistant acute rejection.
P-values were calculated with the use of the Mann–Whitney U-test from the comparison of SSAR vs SRAR as well as reversible acute rejection and graft loss.
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rejection was, the higher the level of urinary fractalkine
became. Patients with SRAR had significantly greater urinary
fractalkine concentration than patients with SSAR, which
revealed high levels of urinary fractalkine predicting SRAR
and poor outcome. It could not be predicted by means of
biopsy, which made the measurement of urinary fractalkine
more valuable. For differentiating SRAR from SSAR and
predicting graft loss, both areas under the ROC curve of
fractalkine were the greatest among those of chemokines.
When elevated creatinine of patients with reversible acute
rejection was successfully controlled, levels of urinary
fractalkine were significantly lower than those at the time
of acute rejection. Meanwhile, patients with graft loss kept
high levels of urinary fractalkine within 1 month after acute
rejection (data no shown). Ordinarily, fractalkine exists in
two forms: membrane-bound and soluble form. The former
works as an adhesion molecule for leukocytes expressing
CX3CR1. Upregulation of fractalkine on endothelial and
epithelial surfaces of rejecting allograft should have a firm
effect on promoting leukocyte adhesion by the fractalk-
ine–CX3CR1 pathway.28 In addition, it was suggested that
fractalkine was important not only in binding NK cells to
endothelial cells, but also in NK cell-mediated endothelium
damage, which may result in vascular injury.29 The soluble
form of fractalkine works as a chemokine. It is a
chemoattractant for leukocytes expressing CX3CR1 (T cells,
monocyte/macrophages, and NK cells) that are upregulated
by proinflammatory cytokines in the rejection process. The
effects of fractalkine–CX3CR1 might be maximized in the
microenvironment of a variety of cytokines during acute
rejection. In the animal model, fractalkine–CX3CR1 interac-
tion was critical for the recruitment of NK cells into graft,
and the absence of CX3CR1 conferred protection from
transplant rejection and the reduction in the number of NK
Table 5 | Summary of ROC curves analysis (for differentiating SSAR from SRAR as well as reversible acute rejection from graft
loss)
Group Area (95% CI) Cut pointa
Sensitivity/
specificity (%) P-value
Fractalkine SSAR vs SRAR 0.771 (0.659–0.884) 233.76 74.4/75.0 o0.001
Reversible AR vs graft loss 0.833 (0.721–0.945) 308.67 100/68.3 0.004
Mig SSAR vs SRAR 0.719 (0.595–0.842) 242.15 64.1/78.6 0.002
Reversible AR vs graft loss 0.733 (0.506–0.961) 557.57 71.4/80.0 0.045
IP-10 SSAR vs SRAR 0.709 (0.585–0.832) 22.35 69.2/67.9 0.004
Reversible AR vs graft loss 0.576 (0.359–0.793) 30.64 71.4/58.3 0.512
MIP-3a SSAR vs SRAR 0.734 (0.616–0.851) 1.54 59.0/82.1 0.001
Reversible AR vs graft loss 0.749 (0.551–0.947) 15.64 57.1/88.3 0.032
Granzyme B SSAR vs SRAR 0.453 (0.312–0.595) 21.68 30.8/92.9% 0.517
Reversible AR vs graft loss 0.580 (0.308–0.852) 29.09 42.9/86.7 0.492
Perforin SSAR vs SRAR 0.533 (0.394–0.671) 27.70 33.3/90.3 0.652
Reversible AR vs graft loss 0.614 (0.363–0.865) 37.97 42.9/85.0 0.325
Mig, chemokine monokine induced by IFN-g; IP-10, IFN-g-inducible protein 10; MIP-3a, macrophage inflammatory protein-3a; SSAR, steroid-sensitive acute rejection; SRAR,
steroid-resistant acute rejection.
ang/mmol creatinine.
Table 6 | Demographic characteristics of patients
Acute rejection (n=67) ATN (n=15) CAN (n=14) No-AR (n=119)
Mean age (years, ±s.d.) 38.76±9.65 39.80±6.35 44.29±11.91 40.55±11.65
Gender, n (%)
Male 41 (61.2) 10 (66.7) 9 (64.3) 66 (55.5)
Female 26 (38.8) 5 (33.3) 5 (35.7) 53 (44.5)
Cause of ESRD, n (%)
Glomerulonephritis 53 (79.1) 13 (86.7) 12 (85.8) 84 (70.6)
Hypertension 2 (3.0) 0 0 3 (2.5)
Obstructive uropathy 1 (1.5) 0 0 3 (2.5)
Diabetes 0 0 1 (14.3) 1 (0.8)
Others 11 (16.4) 2 (13.3) 1 (14.3) 28 (23.6)
Dialysis time (months, ±s.d.) 5.12±3.96 4.96±3.15 5.50±4.99 7.03±8.00
Hepatitis B, n (%) 5 (7.5) 1 (6.7) 1 (7.1) 14 (11.8)
HLA mismatch (±s.d.) 3.87±1.42 3.73±1.15 4.07±1.07 3.69±1.41
Cold ischemia (h, ±s.d.) 8.31±1.97 8.26±1.93 8.93±1.54 8.20±2.36
Panel reactive antibody, n (%)
o10% 62 (92.5) 14 (93.3) 13 (92.9) 112 (94.1)
410% 5 (7.5) 1 (6.7) 1 (7.1) 7 (5.9)
ATN, acute tubular necrosis; CAN, chronic allograft nephropathy; No-AR, stable renal function and no abnormal histological findings.
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cells in the graft.29 Treatment with the anti-CX3CR1 antibody
significantly prolonged allograft survival.28 Furthermore,
polymorphism research of CX3CR1 suggested that outcomes
of acute rejection might be influenced by genetic variant
interaction.30 The above mentioned reasons might suggested
that fractalkine is a more suitable marker for acute rejection
after transplant.
In conclusion, the development of noninvasive techniques
for detection of acute rejection is a major goal for the
transplantation community. The monitoring of biomarkers
in urine may be an important and noninvasive approach for
detecting acute rejection. Among fractalkine, Mig, IP-10,
MIP-3a, granzyme B, and perforin, urinary fractalkine is the
best marker for monitoring acute rejection and predicting the
response to antirejection therapy and short-term graft loss after
acute rejection. A prospective study is needed to make further
assessment of urinary fractalkine and other biomarkers in a
larger and even more ethnically diversified patient population.
MATERIALS AND METHODS
We examined urine samples from 215 renal transplant patients from
June 2001 to December 2005. There were 67 patients with biopsy-
proven acute rejection who had an elevated serum creatinine of 25%
or higher above baseline within 6 months after transplant and 119
patients with stable renal function within 6 months after transplant
and no abnormal histological findings in protocol biopsies
performed 1–2 months after transplant (No-AR). In addition, there
were 15 patients with primary nonfunction showing a prolonged
phase of elevated serum creatinine level and biopsy-proven acute
tubular damage such as epithelial degeneration, necrosis, collapse,
and exfoliation. The absence of any evidence of acute rejection,
glomerular, or other tubulointerstitial diseases was categorized as
acute tubular necrosis (ATN) and there were 14 patients with
biopsy-proven CAN. More detailed demographic characteristics of
four groups are summarized in Table 6 and there were no differences
among characteristics of groups (P40.05). All patients with signs of
infection were excluded from the study. All subjects were primary
grafts received from deceased donors. The study was approved by
the Ethics Committee of the First Affiliated Hospital of College of
Medicine of Zhejiang University according to the Declaration of
Helsinki, and consents were obtained from all subjects.
We obtained 476 fresh first-morning urinary samples from No-
AR patients every 2 weeks during the first 2 months after transplant.
On the day of biopsy, 119, 67, 15, and 14 urinary samples were
collected before biopsy from patients with No-AR, acute rejection,
ATN, and CAN, respectively. Besides, 45 urinary samples were
collected after the end of antirejection therapy at an average of 4
days (range: 1–15 days). Urinary samples were also collected from 80
healthy individuals as controls (average age: 45.22±7.67 years and
male/female: 43/37). In total, 816 urinary samples were collected
from renal transplant patients and healthy controls. All urinary
samples were centrifuged for 10 min at 2500 r.p.m. at 4 1C and the
supernatant was stored at 80 1C for later assay. All biomarker levels
were expressed per millimole of urinary creatinine to correct for
differences in urinary concentration.
We have earlier reported the immunosuppressive protocols used
in Chinese renal allograft recipients.31 Standard triple-drug main-
tenance immunosuppression included a calcineurin inhibitor
(tacrolimus: trough level 5–10 ng/ml, or cyclosporine: trough level
200–300 ng/ml in a half year after transplant), either mycophenolate
or azathioprine and prednisone in tapering doses from 80 to 10 mg/
day within the first month after transplant. Antirejection therapy
after diagnosis of acute rejection was a 3-day course of methyl-
prednisolone (6–10 mg/kg each day). Lack of response to steroid
treatment (graft function had no significant improvement within 3
days or became even worse) was defined as SRAR and was treated
with OKT3 (0.1 mg/kg each day) for 5–7 days. For patients
diagnosed with humoral rejection, plasma exchange therapy was
performed. A single experienced renal pathologist who was unaware
of the result of the study used Banff 97 classification21 to evaluate all
biopsy specimens. Among the 67 patients with acute rejection, 43
were diagnosed as cellular rejection and 24 were humoral rejection
according to antibody-mediated rejection criteria32 and our
previous report.33 For 43 patients with cellular rejection, 24 were
diagnosed as grade I, 18 were grade II, and 1 was grade III.
Enzyme-linked immunosorbent assay: determination of
chemokines and cytotoxic effector molecules in urine
Chemokines (fractalkine, Mig, IP-10, and MIP-3a) and cytotoxic
effector molecules (granzyme B and perforin) were measured in
urinary samples using a commercial human enzyme-linked
immunosorbent assay kit (R&D Systems: Minneapolis, MN, USA;
Abcam: Cambridge, MA, USA). Intra- and interassay variability of
the various enzyme-linked immunosorbent assays could be found in
Supplementary Table 1. All samples were tested in duplicate by a
standardized enzyme-linked immunosorbent assay technique.
Statistical analysis
Statistical analysis was performed using the SPSS software package
(version 11.5; SPSS Inc., Chicago, IL, USA). Comparisons of
biomarkers levels among different groups were performed by the
Kruskal–Wallis test, The Mann–Whitney U-test, and the post hoc test
for unrelated samples. Some relative samples used the Wilcoxon’s
signed-rank test and several other relative samples used Friedman test.
A conventional ROC curve was applied to determine the sensitivities
and specificities for chemokines measurement for patients with acute
rejection, SRAR, or graft loss. The area under the curve was also
calculated. Logistic regression analysis was used to identify the best
marker set for diagnosis of acute rejection and prediction of SRAR.
Results were expressed in the text as mean±s.e.m. unless otherwise
stated. Po0.05 was considered statistically significant.
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